Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Armata Pharmaceuticals Inc's Business Segments
Armata Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 1 | 100% |
Description of Armata Pharmaceuticals Inc
Armata Pharmaceuticals Inc. is a biotechnology company that specializes in the development of therapeutics for antibiotic-resistant infections. The company is headquartered in Marina Del Rey, California and was founded in 2013.
Armata is focused on addressing the global threat of antibiotic resistance, which is a major concern in the healthcare industry due to the increasing number of infections that are resistant to existing antibiotics. The company's mission is to develop novel bacteriophage-based therapies to combat these infections and save lives.
Bacteriophages, or phages, are viruses that specifically target and kill bacteria. Armata utilizes its proprietary PhageBank™ technology, which is a collection of phage isolates with broad spectrum activity against antibiotic-resistant bacteria. These phage candidates can be used for the treatment of various types of infections, including those caused by multi-drug resistant pathogens.
The company has an extensive and diverse pipeline of product candidates, targeting various bacterial infections. Some of the key programs include AP-PA02, which is being developed for the treatment of Pseudomonas aeruginosa infections, and AP-SA01, which is being developed for Staphylococcus aureus infections. These pathogens are known to cause serious and often lethal infections, particularly in hospital settings.
Armata has also developed a proprietary platform called AmpliPhi, which enables the rapid identification and isolation of phage candidates. This platform allows for the production of large quantities of phage products, ensuring a consistent supply for clinical trials and potential commercialization.
The company has also established collaborations and partnerships with leading medical institutions and organizations. These collaborations provide Armata access to expertise and resources for the advancement of its product candidates. Additionally, Armata has received grants and funding from government agencies, including the National Institutes of Health (NIH), to support its research and development efforts.
In addition to its therapeutic programs, Armata is actively involved in research and development activities to further understand phage biology and optimize their use in clinical settings. The company has a team of experienced scientists and researchers who are dedicated to advancing the field of bacteriophage therapy and improving patient outcomes.
Overall, Armata Pharmaceuticals Inc. is a biotechnology company that is at the forefront of developing innovative therapies for antibiotic-resistant infections. With its unique approach using phage therapy, the company aims to revolutionize the way these infections are treated and provide solutions to a critical global health issue.
Armata is focused on addressing the global threat of antibiotic resistance, which is a major concern in the healthcare industry due to the increasing number of infections that are resistant to existing antibiotics. The company's mission is to develop novel bacteriophage-based therapies to combat these infections and save lives.
Bacteriophages, or phages, are viruses that specifically target and kill bacteria. Armata utilizes its proprietary PhageBank™ technology, which is a collection of phage isolates with broad spectrum activity against antibiotic-resistant bacteria. These phage candidates can be used for the treatment of various types of infections, including those caused by multi-drug resistant pathogens.
The company has an extensive and diverse pipeline of product candidates, targeting various bacterial infections. Some of the key programs include AP-PA02, which is being developed for the treatment of Pseudomonas aeruginosa infections, and AP-SA01, which is being developed for Staphylococcus aureus infections. These pathogens are known to cause serious and often lethal infections, particularly in hospital settings.
Armata has also developed a proprietary platform called AmpliPhi, which enables the rapid identification and isolation of phage candidates. This platform allows for the production of large quantities of phage products, ensuring a consistent supply for clinical trials and potential commercialization.
The company has also established collaborations and partnerships with leading medical institutions and organizations. These collaborations provide Armata access to expertise and resources for the advancement of its product candidates. Additionally, Armata has received grants and funding from government agencies, including the National Institutes of Health (NIH), to support its research and development efforts.
In addition to its therapeutic programs, Armata is actively involved in research and development activities to further understand phage biology and optimize their use in clinical settings. The company has a team of experienced scientists and researchers who are dedicated to advancing the field of bacteriophage therapy and improving patient outcomes.
Overall, Armata Pharmaceuticals Inc. is a biotechnology company that is at the forefront of developing innovative therapies for antibiotic-resistant infections. With its unique approach using phage therapy, the company aims to revolutionize the way these infections are treated and provide solutions to a critical global health issue.
Armata Pharmaceuticals Inc. is a significant player in the biotechnology sector, devoted to developing and commercializing bacteriophage-based therapeutics aimed at tackling serious bacterial infections. The companys commitment to addressing the growing threat of antibiotic resistance positions it at the forefront of innovative therapeutic strategies. Below, a detailed breakdown of Armata Pharmaceuticals segments, products, and services is provided:
1. Bacteriophage Therapy
This is the cornerstone of Armata Pharmaceuticals mission. The company focuses on the use of bacteriophages—viruses that specifically infect and destroy bacteria—as a revolutionary approach to treating infections that are resistant to conventional antibiotics. This therapeutic modality is particularly relevant in an era where antibiotic resistance poses a critical healthcare challenge globally.
Product Portfolio
a) PhageBank™
PhageBank™ is Armatas flagship offering that serves as a repository of various bacteriophage strains. Within this compendium, each phage has undergone meticulous selection and characterization, allowing clinicians to quickly access effective treatments tailored to specific resistant pathogens. PhageBank™ provides healthcare professionals with a robust toolkit that can be utilized in emergency settings to address severe bacterial infections promptly.
b) AP-SA01
AP-SA01 is Armata’s lead investigational product specifically targeting Staphylococcus aureus (S. aureus) infections, particularly those caused by Methicillin-resistant Staphylococcus aureus (MRSA). Given MRSA’s status as a major public health concern due to its prevalence and resistance to standard antibiotic treatments, the development of AP-SA01 represents a critical advancement in bacteriophage therapy aimed at mitigating the burden of these infections.
c) AP-PA02
Another promising product in Armata’s pipeline is AP-PA02, which is designed to combat infections caused by Pseudomonas aeruginosa. This bacterium is notorious for its resistance to multiple antibiotic therapies and is associated with various serious infections, especially in immunocompromised patients. The development of AP-PA02 aims to provide targeted therapy that could offer significant improvements over existing treatments, particularly in the context of hospital-acquired infections.
Research and Development
Armata Pharmaceuticals devotes considerable resources to research and development (R&D) to further enhance its product pipeline. The R&D efforts are characterized by a dual focus:
- Preclinical and Clinical Studies: The company engages in comprehensive studies to determine the safety, efficacy, and optimal dosing of its bacteriophage therapies. This rigorous scientific approach ensures that products progress through clinical trials with a robust evidence base supporting their effectiveness.
- Customization and Optimization: Armata is also invested in elucidating mechanisms of action of bacteriophages and identifying ways to enhance their therapeutic effects. This includes tailoring phage combinations to maximize efficacy against resistant bacterial strains.
Collaborations and Partnerships
Recognizing that advancing biopharmaceutical development can benefit from a multidisciplinary approach, Armata collaborates with academic institutions, government entities, and other biotech firms. These partnerships are pivotal in facilitating:
- Knowledge Exchange: Collaborating with research institutions enhances the understanding of bacteriophage biology and its applications.
- Resource Sharing: Working with partners can amplify the resource base, enabling Armata to optimize its research efforts and expedite product development timelines.
Antibiotic Resistance Solutions
In addition to its primary focus on bacteriophage therapies, Armata Pharmaceuticals is actively engaged in broader strategies to tackle antibiotic resistance. This includes research initiatives such as:
- Combination Therapies: Exploring the therapeutic potential of combining bacteriophage treatments with conventional antibiotics to improve overall efficacy and reduce the likelihood of resistance.
- Synergistic Effects Research: Investigating how bacteriophages can work synergistically with antibiotics, potentially leading to treatment approaches that could restore the effectiveness of existing antibiotics against resistant pathogens.
- Adjuvant Therapeutic Approaches: In addition to direct bacterial targeting, Armata examines how phages may enhance the overall therapeutic landscape through supportive roles in immune modulation and inflammation management in conjunction with other therapeutic modalities.
Conclusion
Armata Pharmaceuticals Inc. exemplifies innovation in biopharmaceutical development, primarily through its focus on bacteriophage therapy to address the urgent problem of antibiotic resistance. The company’s diverse product portfolio, commitment to rigorous research and development, strategic collaborations, and a proactive stance against antibiotic resistance collectively highlight its role as a leader in a crucial area of healthcare that promises to reshape the landscape of infectious disease treatment.
1. Bacteriophage Therapy
This is the cornerstone of Armata Pharmaceuticals mission. The company focuses on the use of bacteriophages—viruses that specifically infect and destroy bacteria—as a revolutionary approach to treating infections that are resistant to conventional antibiotics. This therapeutic modality is particularly relevant in an era where antibiotic resistance poses a critical healthcare challenge globally.
Product Portfolio
a) PhageBank™
PhageBank™ is Armatas flagship offering that serves as a repository of various bacteriophage strains. Within this compendium, each phage has undergone meticulous selection and characterization, allowing clinicians to quickly access effective treatments tailored to specific resistant pathogens. PhageBank™ provides healthcare professionals with a robust toolkit that can be utilized in emergency settings to address severe bacterial infections promptly.
b) AP-SA01
AP-SA01 is Armata’s lead investigational product specifically targeting Staphylococcus aureus (S. aureus) infections, particularly those caused by Methicillin-resistant Staphylococcus aureus (MRSA). Given MRSA’s status as a major public health concern due to its prevalence and resistance to standard antibiotic treatments, the development of AP-SA01 represents a critical advancement in bacteriophage therapy aimed at mitigating the burden of these infections.
c) AP-PA02
Another promising product in Armata’s pipeline is AP-PA02, which is designed to combat infections caused by Pseudomonas aeruginosa. This bacterium is notorious for its resistance to multiple antibiotic therapies and is associated with various serious infections, especially in immunocompromised patients. The development of AP-PA02 aims to provide targeted therapy that could offer significant improvements over existing treatments, particularly in the context of hospital-acquired infections.
Research and Development
Armata Pharmaceuticals devotes considerable resources to research and development (R&D) to further enhance its product pipeline. The R&D efforts are characterized by a dual focus:
- Preclinical and Clinical Studies: The company engages in comprehensive studies to determine the safety, efficacy, and optimal dosing of its bacteriophage therapies. This rigorous scientific approach ensures that products progress through clinical trials with a robust evidence base supporting their effectiveness.
- Customization and Optimization: Armata is also invested in elucidating mechanisms of action of bacteriophages and identifying ways to enhance their therapeutic effects. This includes tailoring phage combinations to maximize efficacy against resistant bacterial strains.
Collaborations and Partnerships
Recognizing that advancing biopharmaceutical development can benefit from a multidisciplinary approach, Armata collaborates with academic institutions, government entities, and other biotech firms. These partnerships are pivotal in facilitating:
- Knowledge Exchange: Collaborating with research institutions enhances the understanding of bacteriophage biology and its applications.
- Resource Sharing: Working with partners can amplify the resource base, enabling Armata to optimize its research efforts and expedite product development timelines.
Antibiotic Resistance Solutions
In addition to its primary focus on bacteriophage therapies, Armata Pharmaceuticals is actively engaged in broader strategies to tackle antibiotic resistance. This includes research initiatives such as:
- Combination Therapies: Exploring the therapeutic potential of combining bacteriophage treatments with conventional antibiotics to improve overall efficacy and reduce the likelihood of resistance.
- Synergistic Effects Research: Investigating how bacteriophages can work synergistically with antibiotics, potentially leading to treatment approaches that could restore the effectiveness of existing antibiotics against resistant pathogens.
- Adjuvant Therapeutic Approaches: In addition to direct bacterial targeting, Armata examines how phages may enhance the overall therapeutic landscape through supportive roles in immune modulation and inflammation management in conjunction with other therapeutic modalities.
Conclusion
Armata Pharmaceuticals Inc. exemplifies innovation in biopharmaceutical development, primarily through its focus on bacteriophage therapy to address the urgent problem of antibiotic resistance. The company’s diverse product portfolio, commitment to rigorous research and development, strategic collaborations, and a proactive stance against antibiotic resistance collectively highlight its role as a leader in a crucial area of healthcare that promises to reshape the landscape of infectious disease treatment.